A recent article published in JAMA explores the emerging role of mRNA vaccines as a therapeutic strategy in oncology, highlighting early clinical advances and the scientific rationale underpinning this approach. While mRNA technology gained global attention during the COVID-19 pandemic, its application in cancer treatment reflects a broader shift toward personalised immunotherapy.
Unlike traditional vaccines designed to prevent infectious disease, cancer mRNA vaccines are tailored to an individual’s tumour. These vaccines encode tumour-specific neoantigens, enabling the immune system to recognise malignant cells as targets. This approach builds on the observation that some patients can mount spontaneous immune responses against their tumours, suggesting that this process can be therapeutically enhanced.
CLINICAL SUMMARY
What was examined
A narrative overview of emerging evidence on mRNA-based cancer vaccines, including early-phase clinical trials across multiple tumour types.
Key findings
- Personalised mRNA vaccines can induce tumour-specific T-cell responses, with responses associated with improved recurrence-free survival in some cancers
- Durable immune responses have been observed in subsets of patients, including in pancreatic cancer and triple-negative breast cancer
- Early clinical activity has also been reported in difficult-to-treat malignancies such as glioblastoma
Clinical implications
- mRNA vaccines represent a promising immunotherapeutic strategy aligned with precision oncology
- Clinical activity appears limited to patients mounting an immune response, highlighting the need for predictive biomarkers
- Ongoing phase 2 and larger trials will be critical to establish efficacy and define integration with standard therapies
Early-phase clinical data are beginning to demonstrate proof of concept across several tumour types. In pancreatic ductal adenocarcinoma, a malignancy with historically poor outcomes, personalised mRNA vaccination has been evaluated alongside checkpoint inhibition and chemotherapy. In a phase 1 study, vaccine-induced neoantigen-specific T-cell responses were observed in a subset of patients, with these responses associated with improved recurrence-free survival compared with non-responders. Follow-up data suggest that these immune responses may be durable, with reduced recurrence rates observed at three years among those mounting a robust response.
Featured Event
Similar strategies are being explored in other hard-to-treat cancers. In triple-negative breast cancer, early findings from small studies indicate that individualised mRNA vaccines can generate functional T-cell responses that persist for several years, with a proportion of patients remaining relapse-free during extended follow-up. In glioblastoma, an aggressive brain tumour with limited treatment options, experimental mRNA vaccine approaches have demonstrated rapid immune activation, with very early signals of potential survival benefit reported in small cohorts.
A key advantage of mRNA platforms lies in their flexibility and speed of development. Once tumour sequencing identifies relevant neoantigens, personalised vaccines can be designed and manufactured relatively quickly compared with traditional biologics. This adaptability may allow treatment to keep pace with tumour evolution, a major challenge in oncology. Furthermore, advances in delivery systems, including lipid nanoparticle formulations and novel clustering approaches, are being investigated to enhance immune activation and improve therapeutic efficacy.
Despite these promising signals, important challenges remain. Not all patients generate effective immune responses, and the factors determining response—such as tumour mutational burden, antigen selection, and immune microenvironment—are still being elucidated. Additionally, most current evidence derives from small, early-phase studies, and larger randomised trials are required to confirm clinical benefit and define optimal combinations with existing therapies. Several such trials are ongoing and are expected to provide more definitive evidence in the near term.
Overall, mRNA vaccines represent a potentially transformative addition to the oncology treatment landscape, aligning with the broader movement toward precision medicine. While still investigational, their ability to induce durable, tumour-specific immune responses suggests they have the potential to improve outcomes in cancers that have historically been resistant to conventional approaches.
Paper: Rubin R. How mRNA Vaccines Could Help Treat Cancer. JAMA. Published online April 10, 2026. doi:10.1001/jama.2026.2088 Access online here.
